Inhibition of CXCR4–CXCL12 chemotaxis in melanoma by AMD11070

Ten Years of Progress in Melanoma

(2017) John A. Thompson   Journal of the National Comprehensive Cancer Network

Overexpression of the chemokine receptors CXCR4, CCR7, CCR9, and CCR10 in human primary cutaneous melanoma: a potential prognostic value for CCR7 and CCR10?

(2012) Laura Kühnelt-Leddihn et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines

(2012) Brenden Chen et al.   PLoS One

Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation

(2012) G. O'Boyle et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The molecular pharmacology of AMD11070: An orally bioavailable CXCR4 HIV entry inhibitor

(2011) Renee M. Mosi et al.   BIOCHEMICAL PHARMACOLOGY

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome

(2011) D. C. Dale et al.   BLOOD

Oncogenic B-RAF Signaling in Melanoma Impairs the Therapeutic Advantage of Autophagy Inhibition

(2011) J. L. Armstrong et al.   CLINICAL CANCER RESEARCH

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

CXCL12 (SDF-1)/CXCR4 Pathway in Cancer

(2010) B. A. Teicher et al.   CLINICAL CANCER RESEARCH

Hepatic stellate cells express functional CXCR4: Role in stromal cell-derived factor-1α-mediated stellate cell activation

(2009) Feng Hong et al.   HEPATOLOGY

T cell extravasation: Demonstration of synergy between activation of CXCR3 and the T cell receptor

(2009) Peter Newton et al.   MOLECULAR IMMUNOLOGY

Increasing Melanoma Cell Death Using Inhibitors of Protein Disulfide Isomerases to Abrogate Survival Responses to Endoplasmic Reticulum Stress

(2008) P. E. Lovat et al.   CANCER RESEARCH

Tumour cell survival signalling by the ERK1/2 pathway

(2008) K Balmanno et al.   CELL DEATH AND DIFFERENTIATION